Press release content from Business Wire. The AP news staff was not involved in its creation.
UKONIQ™ (umbralisib) Now Approved by the FDA; Onco360® Selected as Exclusive Specialty Pharmacy Partner
February 8, 2021 GMT
LOUISVILLE, Ky.--(BUSINESS WIRE)--Feb 8, 2021--
Onco360 ®, the nation’s largest independent Oncology Pharmacy, has been selected by TG Therapeutics, Inc. to be the exclusive specialty pharmacy partner for UKONIQ TM (umbralisib), a new oral treatment for adult patients with relapsed refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed refractory follicular lymphoma who have received at least three prior lines of systemic therapy. These indications are approved under accelerated approval based on overall response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial.